|

SHR-1316 Clinical Trials

4 actively recruiting trials

▼ -2 trials since July 2026

Also known as: HTI-1088

Pipeline

Phase 2: 3Phase 1/2: 1

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.2
  • Fudan University2

Indications

  • Cancer4
  • Breast Cancer2
  • HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer1
  • Hormone Receptor Negative Tumor1
  • Hormone Receptor Positive Tumor1

Other4 trials

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.